Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanobiotix ( (NBTX) ) has shared an announcement.
On November 14, 2025, Nanobiotix announced its updated voting rights and share capital information as of October 31, 2025. The company reported 48,237,471 shares outstanding, with 50,267,962 theoretical voting rights and 50,245,844 exercisable voting rights. This announcement is significant for stakeholders as it provides transparency in shareholder voting power and aligns with regulatory requirements.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, specializing in innovative, physics-based therapeutic approaches. Established in 2003, the company focuses on oncology, bioavailability and biodistribution, and central nervous system disorders, with over 25 patent families. It is listed on Euronext Paris and Nasdaq, with subsidiaries in the United States.
Average Trading Volume: 90,553
Technical Sentiment Signal: Buy
Current Market Cap: $1.03B
For an in-depth examination of NBTX stock, go to TipRanks’ Overview page.